Vorinostat Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 100 mg
Reference Brands: Zolinza (USA/EU), Vornat (India)
Category:
Oncology Cancer Care
Vorinostat is available in Capsules
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vorinostat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vorinostat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Vorinostat is an anticancer medication used in the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin lymphoma that primarily affects the skin. It is generally prescribed for patients whose disease persists, worsens, or returns during or after treatment with other therapies. Vorinostat has demonstrated effectiveness in controlling disease progression and improving symptoms in patients with advanced or treatment-resistant CTCL.
Vorinostat belongs to a class of medicines known as histone deacetylase (HDAC) inhibitors. These drugs work by altering gene expression within cancer cells, which can slow the growth of malignant cells, stop their proliferation, and promote programmed cell death (apoptosis). Through this targeted mechanism, Vorinostat helps disrupt the survival and expansion of cancerous T-cells.
The drug is considered a significant advancement in the management of CTCL due to its efficacy and generally well-tolerated safety profile. In addition to its approved use, Vorinostat is also being studied for potential benefits in the treatment of other types of cancers. Ongoing research is evaluating its role both as a single therapy and in combination with other anticancer treatments to improve outcomes in various malignancies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing